![Picture](/uploads/5/2/4/6/52466757/editor/onconano-logo.png?1634237576)
“We are excited by the positive preclinical results for ONM-501 recently presented at AACR. STING plays a crucial role in mediating our innate immune systems but has consistently been a challenging pathway to target,” said Martin Driscoll, Chief Executive Officer of OncoNano Medicine, Inc...(read more)